PCSK9 INHIBITOR INITIATION AMONG VETERANS ACCORDING TO THE 2018 AHA/ACC BLOOD CHOLESTEROL GUIDELINES

Catherine G. Derington,Jordan B. King,Robert S. Rosenson,Bharat Poudel,Keri L. Monda,Ann Marie Navar,Katherine E. Mues,James R. Cook,Vanessa Stevens,Jennifer S. Herrick,Paul Muntner,Lisandro D. Colantonio,Adam P. Bress

PCSK9 INHIBITOR INITIATION AMONG VETERANS ACCORDING TO THE 2018 AHA/ACC BLOOD CHOLESTEROL GUIDELINES

2020

Catherine G. Derington
Jordan B. King
Robert S. Rosenson
Bharat Poudel
Keri L. Monda
Ann Marie Navar
Katherine E. Mues
James R. Cook
Vanessa Stevens
Jennifer S. Herrick
Paul Muntner
Lisandro D. Colantonio
Adam P. Bress

Proprotein convertase subtilisin/kexin type 9 inhibitor antibodies (PCSK9i) have been shown prevent cardiovascular disease events in patients with atherosclerotic cardiovascular disease (ASCVD). Analyzing the characteristics of patients who initiate and do not initiate a PCSK9i may identify

Keywords:

Diabetes mellitus
PCSK9
blood cholesterol
Cardiology
Medicine
Internal medicine
Disease
Proprotein convertase
Kexin
Antibody
Subtilisin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations